Compare BIIB & TS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | TS |
|---|---|---|
| Founded | 1978 | 2001 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 20.8B |
| IPO Year | 1991 | N/A |
| Metric | BIIB | TS |
|---|---|---|
| Price | $181.61 | $41.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 5 |
| Target Price | ★ $176.48 | $42.60 |
| AVG Volume (30 Days) | ★ 1.9M | 963.0K |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 4.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 10.97 | 1.86 |
| Revenue | $10,065,900,000.00 | ★ $11,831,250,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | $16.52 | ★ $10.57 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $110.04 | $30.06 |
| 52 Week High | $185.17 | $41.76 |
| Indicator | BIIB | TS |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 59.34 |
| Support Level | $174.53 | $39.38 |
| Resistance Level | $182.94 | $41.59 |
| Average True Range (ATR) | 5.22 | 0.69 |
| MACD | 0.25 | -0.07 |
| Stochastic Oscillator | 83.54 | 72.37 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.